| Followers | 254 |
| Posts | 30070 |
| Boards Moderated | 2 |
| Alias Born | 07/08/2009 |
Monday, August 14, 2023 8:53:23 AM
Seen this post from another.
In my opinion possible positive speculation that can drive price
1) surprise good earnings and update
2) announce bid requirement extension
3) insiders or private company buying shares
Recent TIVC News
- Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod • ACCESS Newswire • 03/31/2026 12:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 09:34:51 PM
- Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference • ACCESS Newswire • 03/27/2026 03:30:00 PM
- Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome • ACCESS Newswire • 03/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:25:57 PM
- Tivic Reports Full Year 2025 Results • ACCESS Newswire • 03/25/2026 08:05:00 PM
- Tivic Health CEO Letter to Shareholders • ACCESS Newswire • 03/24/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 09:15:08 PM
- Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET • ACCESS Newswire • 03/20/2026 07:35:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/20/2026 01:14:41 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 09:27:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2026 01:30:42 PM
- Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma • ACCESS Newswire • 03/04/2026 01:30:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/27/2026 09:05:24 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 02/23/2026 10:15:11 PM
- Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10 • ACCESS Newswire • 02/18/2026 02:15:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/09/2026 09:46:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:45:28 PM
- Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting • ACCESS Newswire • 01/28/2026 01:30:00 PM
- Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference • ACCESS Newswire • 01/26/2026 03:10:00 PM
- Tivic CEO To Present at the Upcoming Emerging Growth's January 2026 Virtual Conference • ACCESS Newswire • 01/20/2026 10:50:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/20/2026 09:07:17 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/20/2026 09:07:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 02:00:59 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/20/2026 05:15:24 AM

